May 15, 2020 / 1:55 PM / 22 days ago

BRIEF-Editas Medicine Presents Pre-Clinical Data Supporting The Use Of CRISPR-Cas12a To Edit Induced Pluripotent Stem Cells For The Development Of Engineered Cell Immunotherapies

May 15 (Reuters) - Editas Medicine Inc:

* EDITAS MEDICINE PRESENTS PRE-CLINICAL DATA SUPPORTING THE USE OF CRISPR-CAS12A TO EDIT INDUCED PLURIPOTENT STEM CELLS FOR THE DEVELOPMENT OF ENGINEERED CELL IMMUNOTHERAPIES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below